Dulaglutide
- Generic Name
- Dulaglutide
- Brand Names
- Trulicity
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 923950-08-7
- Unique Ingredient Identifier
- WTT295HSY5
- Background
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was appro...
- Indication
Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular r...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT06739122
- Locations
- 🇺🇸
D&H Tamarac Research Center, LLC, Tamarac, Florida, United States
The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria
- Conditions
- Interventions
- First Posted Date
- 2024-09-25
- Last Posted Date
- 2024-09-25
- Lead Sponsor
- Attikon Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06611904
- Locations
- 🇬🇷
Attikon University General Hospital, Chaidari, Attica, Greece
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06533527
- Locations
- 🇺🇸
Cleveland Clinic, Weston, Florida, United States
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
- Conditions
- Interventions
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Beijing Dongfang Biotech Co., Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT06257966
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Phase 3 Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Target Recruit Count
- 618
- Registration Number
- NCT06235086
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- National and Kapodistrian University of Athens
- Target Recruit Count
- 78
- Registration Number
- NCT05946148
- Locations
- 🇬🇷
"Hippocration" General Hospital of Athens, Athens, Attiki, Greece
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
- Conditions
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 623
- Registration Number
- NCT05680129
- Locations
- 🇨🇳
ZHONGSHAN Hospital, Shanghai, Shanghai, China
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT05659537
- Locations
- 🇮🇳
Life Care Hospital and Research Centre, Bangalore, Karnataka, India
🇮🇳Akshay Hospital, Pune, Maharashtra, India
🇮🇳Virinchi Hospital, Hyderabad, Telangana, India
A Study of IBI362 in Participants With Type 2 Diabetes
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 731
- Registration Number
- NCT05606913
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijin, China
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 282
- Registration Number
- NCT05564039
- Locations
- 🇺🇸
Juno Research, Houston, Texas, United States
🇺🇸Biopharma Informatic, LLC, Houston, Texas, United States
🇷🇴Diabdana, Oradea, Bihor, Romania
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.